Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
UPDATE: Altera (ALTR), ZMDI Enter Licensing Agreement
August 3, 2015 8:06 AM EDT(Updated - August 3, 2015 8:07 AM EDT)
Altera Corp (NASDAQ: ALTR) announced the signing of a licensing agreement with ZMDI (Zentrum Mikroelektronik Dresden AG), a German-based analog and mixed signal semiconductor company. Altera will leverage ZMDI's world-class digital power management technology to integrate advanced multi-mode digital control (MMDC) power capabilities into Enpirion® PowerSoC devices. A design team of digital power experts will focus on expanding the control, adaptability and power saving features of Enpirion PowerSoCs to further improve the power efficiency of Altera FPGAs and SoCs.
The ZMDI digital power technology complements Altera's existing... More
Array Biopharma (ARRY) Tops Q4 EPS by 7c
August 3, 2015 8:05 AM EDTArray Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $10.29 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
... More